Taylor D
Maudsley Hospital, London.
Br J Psychiatry. 1995 Nov;167(5):575-80. doi: 10.1192/bjp.167.5.575.
The selective serotonin reuptake inhibitors (SSRIs) are now widely used in the treatment of depressive illness. Interest has grown in the use of SSRIs as alternatives to tricyclic antidepressants (TCAs) and in the therapeutic use of combinations of SSRIs and TCAs in refractory depression.
MEDLINE and PSYCLit literature searches were conducted. Reference sections from papers retrieved were scrutinised for other relevant reports.
Of 41 relevant articles identified, 35 were selected for review.
Fluoxetine, fluvoxamine, paroxetine and sertraline may substantially increase TCA plasma levels when given concurrently. Such interactions may give rise to adverse effects. The effect of sertraline may be less profound than that of fluoxetine, fluvoxamine and paroxetine. Limited data suggest that citalopram may not affect TCA serum levels. There is scant literature evidence to support the use of SSRIs in combination with TCAs as a treatment for refractory depression.
选择性5-羟色胺再摄取抑制剂（SSRI）目前广泛用于治疗抑郁症。人们越来越关注将SSRI用作三环类抗抑郁药（TCA）的替代品，以及在难治性抑郁症中联合使用SSRI和TCA的治疗用途。
进行了MEDLINE和PSYCLit文献检索。对检索到的论文的参考文献部分进行了审查，以查找其他相关报告。
在确定的41篇相关文章中，选择了35篇进行综述。
氟西汀、氟伏沙明、帕罗西汀和舍曲林与TCA同时给药时，可能会大幅提高TCA的血浆水平。这种相互作用可能会产生不良反应。舍曲林的作用可能不如氟西汀、氟伏沙明和帕罗西汀那么显著。有限的数据表明，西酞普兰可能不会影响TCA的血清水平。几乎没有文献证据支持将SSRI与TCA联合用于治疗难治性抑郁症。
